Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Releases Final Label Revision And TA ANDA Amendment Guidances

The FDA Aims To Improve The Development, Review, And Approval Process Of Generic Drugs

Executive Summary

While the new guidance on ANDA label revision “provides clear expectations” from the FDA, the revised guidance on amendments to tentatively approved ANDAs is yet to answer questions from AAM.

You may also be interested in...

ANDA Sponsors Need US FDA Permission To Avoid Last-Minute Label Update Delays

Under changes in the 2022 appropriations bill, generic drug applications can be approved even if a last-minute labeling update is needed, but sponsors risk product misbranding if the CBE is late.

FDA And Industry Set Out GDUFA III Priorities

Both first-cycle approvals and priority assessment improvements have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.

Cosette Launches First US Generic To AbbVie’s Rectiv

Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts